EUVIMEDEUVIMED entdecken
Crossref

NAFLD vs MASLD (Metabolic Dysfunction–Associated Steatotic Liver Disease)—Why the Need for a Change of Nomenclature?

Amalia Gastaldelli iD, Philip N Newsome iD

The Journal of Clinical Endocrinology & Metabolism · 17.06.2025 · 110 (7) · e2407-e2410

DOI: 10.1210/clinem/dgaf094 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 19.02.2025. Verfasst von Amalia Gastaldelli und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cardiometabolic Risk Laboratory, Institute of Clinical Physiology (IFC), National Research Council (CNR), 56124 Pisa, Italy. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Terminology as Topic, Fatty Liver, Metabolic Diseases. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Several reasons led to the change in the nomenclature from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction–associated steatotic liver disease (MASLD); the most important being limitations due to the reliance on exclusionary confounder terms and the use of potentially stigmatizing language (the terms “nonalcoholic” and “fatty”). The new name was decided through a Delphi process and now includes in the name, and definition, the metabolic origin (the presence of at least 1 of 5 cardiometabolic risk factors) without the stigmatizing terms. The recognition of a new category termed “metabolic and alcohol related/associated liver disease” (MetALD) opens up a new area for exploration although the relative contribution of alcohol and metabolic risk factors requires further evaluation as does the evidencing at a patient rather than population level.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseTerminology as TopicFatty LiverMetabolic DiseasesHumans

Stichwörter der Autor:innen

MASHMASLDfibrosisfree fatty acidsglucagon like peptide 1 receptor agonistsinsulin resistance

Autor:innen und Institutionen

  • Cardiometabolic Risk Laboratory, Institute of Clinical Physiology (IFC), National Research Council (CNR), 56124 Pisa, Italy.
  • Roger Williams Institute of Liver Studies, School of Immunology & Microbial Sciences, Faculty of Life Sciences and Medicine, King's College London, Foundation for Liver Research and King's College Hospital, London SE5 9…

ORCID-Profile: Amalia Gastaldelli, Philip N Newsome

Zitieren

APA

Gastaldelli, A., & Newsome, P. N. (2025). NAFLD vs MASLD (Metabolic Dysfunction–Associated Steatotic Liver Disease)—Why the Need for a Change of Nomenclature?. The Journal of Clinical Endocrinology & Metabolism, 110(7), e2407-e2410. https://doi.org/10.1210/clinem/dgaf094

Vancouver

Gastaldelli A, Newsome PN. NAFLD vs MASLD (Metabolic Dysfunction–Associated Steatotic Liver Disease)—Why the Need for a Change of Nomenclature?. The Journal of Clinical Endocrinology & Metabolism. 2025;110(7):e2407-e2410. doi:10.1210/clinem/dgaf094

BibTeX
@article{Gastaldelli2025,
  author = {Gastaldelli, Amalia and Newsome, Philip N},
  title = {NAFLD vs MASLD (Metabolic Dysfunction–Associated Steatotic Liver Disease)—Why the Need for a Change of Nomenclature?},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {7},
  pages = {e2407--e2410},
  doi = {10.1210/clinem/dgaf094}
}
Kostenlos starten →